AbbVie reports $61.2 billion revenue and announces quarterly dividend

AbbVie Inc. is transitioning its pharmaceutical focus from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion, an 8.6% increase from the previous year, with a net income of $4.2 billion.

AbbVie’s distribution relies heavily on three major wholesalers: McKesson & Co., Cardinal Health, and Cencora. The company has also announced a quarterly dividend of $1.73 per share, with an ex-dividend date of October 15, 2026, and a payment date of November 16, 2026. Based on recent stock prices, the annualized gross dividend yield is approximately 2.5%.

In the broader healthcare sector, AbbVie is frequently compared to Eli Lilly & Co., which is currently expanding its presence in the metabolic drug market, specifically targeting diabetes, obesity, and Alzheimer's disease.